Fulcrum Therapeutics Q3 2023: net loss $24M, Phase 3 enrollment complete, cash runway extended into 2026

Fulcrum Therapeutics, Inc.

2023-Q3 EPS reported -$1.19 revenue$1,934,000

Completed enrollment in Phase 3 REACH trial of losmapimod for FSHD; topline data expected Q4 2024.
FDA lifted clinical hold for pociredir in sickle cell disease; Phase 1b trial reinitiation underway with amended protocol.
Net loss of $24.0M for Q3 2023 vs $23.7M in prior-year quarter; R&D expenses increased to $18.2M.
Cash, cash equivalents, and marketable securities $257.1M as of Sep 30, 2023; cash runway extended into 2026.
Collaboration revenue $0.8M, down from $1.2M in Q3 2022.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Fulcrum Therapeutics, Inc. reported third quarter of 2023 results: revenue $0.8 million, net income $24.0 million.

Period: third quarter of 2023
Revenue: $0.8 million
Net income: $24.0 million
Result: reported results

Exact text from the filing

cash, cash equivalents, and marketable securities were $257.1 million, as compared to $202.9 million as of December 31, 2022. • Collaboration Revenue: Collaboration revenue was $0.8 million for the third quarter of 2023 as compared to $1.2 million for the third quarter of 2022. • R&D Expenses: Research and development expenses were $18.2 million for the third

View on SEC.gov

Browse all earnings releases →

Fulcrum Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-059753

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.